Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc (SBFM) combines generic drug commercialization with cutting-edge research in oncology and antiviral therapies. This news hub provides investors and healthcare stakeholders with essential updates about the company's operational developments and scientific advancements.
Access timely press releases covering regulatory milestones, financial results, and research breakthroughs. Our curated collection includes updates on SBFM's generic drug portfolio through subsidiary Nora Pharma, plus progress reports on proprietary initiatives like the K1.1 mRNA-LNP cancer treatment and PLpro protease inhibitor program.
Key content categories include quarterly earnings announcements, partnership disclosures, clinical trial updates, and market expansion news. All materials are sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to SBFM's latest developments. Regularly updated content helps stakeholders monitor both the company's established generics business and its innovative drug development pipeline in critical therapeutic areas.
Sunshine Biopharma (NASDAQ:SBFM) reported strong financial results for Q2 2024, with significant revenue growth. Key highlights include:
- Q2 revenues of $9,303,067, up 67% year-over-year
- YTD revenues of $16,844,113, up 61% year-over-year
- Q2 net loss decreased by 45% to $(494,300)
- YTD net loss decreased by 32% to $(1,778,101)
- Shareholders' Equity grew 11% to $23,489,865
The company attributes this growth to new product launches and expanded marketing efforts by its Canadian subsidiary, Nora Pharma Inc. CEO Dr. Steve Slilaty expressed confidence in achieving profitability through innovative strategies and operational optimization.
Sunshine Biopharma (NASDAQ:SBFM) has announced a 1-for-20 reverse stock split, effective August 8, 2024. This strategic move aims to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The pharmaceutical company, which focuses on life-saving medicines in oncology and antivirals, is taking this step to maintain its position on the Nasdaq exchange. This decision highlights the company's commitment to meeting regulatory standards and potentially improving its market position.
Sunshine Biopharma (NASDAQ:SBFM) announced its 2024 first-quarter results, showing a 54% increase in gross revenues to $7.54 million, up from $4.89 million in the same period of 2023. The surge is attributed to new product launches and expanded marketing by its Canadian subsidiary, Nora Pharma. Despite the revenue growth, the company reported a net loss of $1.28 million, an improvement over the $1.70 million loss in the first quarter of 2023. The company also completed a public offering in February 2024, raising $10 million in gross proceeds, with $8.52 million net proceeds. Sunshine Biopharma is focused on achieving profitability.
FAQ
What is the current stock price of Sunshine Biopharma (SBFM)?
What is the market cap of Sunshine Biopharma (SBFM)?
